Akari Therapeutics Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Akari Therapeutics Plc (the "Company") on September 19, 2025. The filing details material definitive agreements regarding debt and warrant amendments, the closing of a second tranche of a notes offering, and the announcement of preclinical data for a novel antibody drug conjugate (ADC) payload.
Key Financial Metrics and Capital Activities
- Debt Issuance: The Company closed the second tranche of its August 2025 Notes Offering, issuing $625,000 in aggregate principal amount for a purchase price of $500,000 (reflecting a 20% original issuance discount).
- Total Notes Outstanding: Following this closing, the aggregate principal amount of August 2025 Notes issued is approximately $3.5 million.
- Interest Payment: In connection with the amendment of April 2023 Notes, the Company agreed to pay holders approximately $81,700 representing accrued interest through September 30, 2025.
- Revenue and Profit: The filing text does not provide specific revenue, profit, cash flow, or margin figures for the reporting period.
Material Changes and Agreements
Amendment of April 2023 Notes and Warrants
On September 19, 2025, the Company amended terms for convertible promissory notes and warrants assumed from Peak Bio, Inc. during the November 2024 merger:
- Notes Maturity: Extended from October 2024 to August 31, 2026.
- Conversion Price: Reduced from $2.04 to $0.81 per ADS.
- Voluntary Conversion: Holders may now voluntarily convert principal and accrued interest into ADSs at any time.
- Warrants Expiration: Extended from the original term to August 31, 2030.
- Warrant Terms: Exercise price reduced to $0.81 per ADS; total ADSs issuable amended to 342,420.
Amendment of Series A Warrants
In connection with the August 2025 Notes Offering closing, the Company amended Series A Warrants held by certain investors:
- Expiration Extension: Extended from 2026 to April 25, 2030.
- Scope: Applies to Series A Warrants to purchase 4,891,272 ADSs held by August 2025 Note Investors.
Outlook, Management Commentary, and Risks
Preclinical Data Announcement
The Company announced preclinical data for its novel ADC spliceosome modulating payload, PH1, targeting tumors driven by alternative splicing, specifically the Androgen Receptor splice variant 7 (AR-V7) in prostate cancer:
- Efficacy in Refractory Models: PH1 suppressed AR-V7 expression in the 22Rv1 hormone-refractory model, whereas standard Androgen Receptor Pathway Inhibitors (ARPIs) had no effect.
- Efficacy in Sensitive Models: In hormone-sensitive LnCAP cells, PH1 showed benefit as a single agent and an additive effect when combined with Xtandi or Erleada.
- Strategic Hypothesis: Management believes combining ARPIs with PH1 ADCs may slow the development of resistance and AR-V7-driven tumor progression.
- Next Steps: The Company plans to present this data at an upcoming scientific conference and test the combination hypothesis in future research.
Risks and Forward-Looking Statements
The filing includes standard cautionary notes regarding forward-looking statements. Key risks identified include the need for additional capital, potential delays in research and development, uncertainty regarding clinical trial replication, intellectual property risks, and supply chain interruptions.
Investor Verification Checklist
- Verify the dilution impact of the amended conversion price ($0.81 per ADS) on the April 2023 Notes and the increased warrant exercise volume.
- Confirm the total outstanding debt obligations, specifically the $3.5 million principal of August 2025 Notes and the $0.7 million principal of April 2023 Notes.
- Review the full text of the Letter Agreement (Exhibit 10.1) for specific covenants and default provisions related to the amended notes.
- Monitor upcoming scientific conferences for the presentation of PH1 preclinical data to assess the validity of the AR-V7 suppression claims.
- Assess the Company's cash runway given the recent capital raises and the ongoing need for funding in preclinical development stages.